CD38: Master regulator of NAD and a therapeutic target

Created using ChatSlide

This literature-focused review examines the CD38–NAD axis as a central mechanism linking NAD depletion to aging, inflammation, metabolic dysfunction, neurodegeneration, fibrosis, and immune-mediated disease. It synthesizes evidence on CD38 enzymology, NAD-dependent signaling, disease-associated expression patterns, and translational strategies, including CD38 inhibition, NAD restoration, biomarker-guided stratification, and safety considerations.